Resources
The below resources can further assist healthcare providers to educate patients about Restless Legs Syndrome (RLS) and MIRAPEX:
Patient Education materials can help patients better understand RLS and its treatment
Related Links provides a listing of suggested websites for further information about RLS
MIRAPEX has no predicted P450 interactions9—an important consideration in patients on multiple medications.
MIRAPEX has no predicted P450 interactions9—an important consideration in patients on multiple medications. Contraindications
Familiarize yourself with three typical patient case studies reflective of diagnosing restless legs syndrome. Learn more
Familiarize yourself with three typical patient case studies reflective of diagnosing restless legs syndrome. Learn more
Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).
Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
